source
- Amgen halts development of early-stage obesity drug AMG 513, shifting focus to phase-3 candidate MariTideAmgen announced it is stopping work on AMG 513, an early-stage obesity therapy, during its second-quarter earnings call. The decision follows a previous FDA clinical hold in early 2025 that was la…
- Expedition Therapeutics raises $115M Series B to fund phase 2 COPD trial of DPP1 inhibitorExpedition Therapeutics, backed by Sanofi, announced a $115 million Series B financing round. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, and existing i…